Anzeige
Erschienen in:
01.06.2023 | Original Article
High-dose planned adaptive helical tomotherapy for cutaneous angiosarcoma of the scalp
Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2024
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The purpose of this study was to investigate the feasibility and effectiveness of high-dose planned adaptive intensity-modulated radiation therapy (IMRT) with helical tomotherapy (HT) for cutaneous angiosarcoma (cAS) of the scalp.
Methods
This retrospective cross-sectional included a total of 12 consecutive patients with cAS of the scalp who underwent high-dose planned adaptive IMRT with HT. Prescribed doses were 72.5–74 Gy in 35–37 fractions for the gross tumor volume plus a 1–2 mm margin (PTV1), 58–60 Gy in 29–30 fractions for the clinical target volume plus a 2–3 mm margin (PTV2), and 46 Gy in 23 fractions for the clinical target volume plus a 5–15 mm margin (PTV3) over periods of 7.5, 6 and 4.5 weeks, respectively.
Results
The estimated 1‑year and 2‑year overall survival rate were 65.6% and 27.3%, respectively, and the local progression-free survival at 2 years was 74.1%. All local recurrences were either in or marginal to the PTV2 or PTV3. No local recurrence was observed in the PTV1. All patients tolerated the treatment without grade 3 or higher adverse events during the radiotherapy period. No late adverse events were observed during the follow-up period.
Conclusion
Planned adaptive high-dose IMRT with HT has the potential to improve local control rate without increasing adverse events.